A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes
Table 1
Glycemic and lipid assessment parameters from baseline to the end of study treatment with continuous subcutaneous insulin infusion (group A) or basal insulin glargine plus oral hyperglycemic agent (group B).
Clinical characteristic†
Group A ()
Group B ()
value
Age
47.6 ± 10.9
49.0 ± 9.9
0.590
Male (, %)
25, 71.4
23, 69.7
0.876
BMI (kg/m2)
25.4 ± 3.7
25.3 ± 2.8
0.839
WC (cm)
90.9 ± 8.0
90.8 ± 8.2
0.937
Baseline HbA1c (%) [mmol/mol]
11.38 ± 2.00 [100.9]
11.17 ± 2.00 [98.6]
0.671
△HbA1c (%) [mmol/mol]
−0.94 ± 0.50‡ [−10.3]
−0.80 ± 0.35‡ [−8.7]
0.190
Baseline glycated albumin (%)
32.70 ± 7.00
31.74 ± 9.04
0.625
△Glycated albumin (%)
−6.44 ± 3.23‡
−6.42 ± 3.56‡
0.970
Baseline FPG (mmol/L)
12.72 ± 2.87
12.41 ± 3.33
0.681
△FPG (mmol/L)
−5.85 ± 2.92‡
−7.41 ± 3.41‡
0.046
Baseline 2-hour PPG (mmol/L)
21.73 ± 3.93
20.79 ± 4.93
0.389
△2-hour PPG (mmol/L)
−7.19 ± 4.18‡
−9.78 ± 4.94‡
0.022
Baseline LDL-C (mmol/L)
3.44 ± 1.24
3.48 ± 1.06
0.905
△LDL-C (mmol/L)
−0.76 ± 0.95‡
−1.04 ± 0.91‡
0.221
Baseline total cholesterol (mmol/L)
5.21 ± 1.27
5.63 ± 1.21
0.165
△Total cholesterol (mmol/L)
−0.95 ± 0.97‡
−1.43 ± 1.02‡
0.054
Baseline HDL-C (mmol/L)
1.09 ± 0.25
1.17 ± 0.40
0.289
△HDL-C (mmol/L)
−0.03 ± 0.16
−0.10 ± 0.15‡
0.087
Baseline triglycerides (mmol/L)
1.51 ± 0.70
2.19 ± 1.23
0.006
△Triglycerides (mmol/L)
−0.10 ± 0.64
−0.50 ± 1.08‡
0.062
†Data are mean (standard deviation) unless otherwise stated; ‡significant change from baseline (). △: change from baseline; BMI: body mass index; WC: waist circumference; FPG: fasting plasma glucose; PPG: postprandial plasma glucose; HbA1c: glycated hemoglobin; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol.
